×

Modulation of transthyretin expression

  • US 20050244869A1
  • Filed: 04/01/2005
  • Published: 11/03/2005
  • Est. Priority Date: 04/05/2004
  • Status: Abandoned Application
First Claim
Patent Images

1. An antisense compound 13 to 80 nucleobases in length targeted to a nucleic acid molecule encoding human transthyretin, wherein said compound inhibits the expression of human transthyretin mRNA by at least 10%.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×